TFP Fertility: Can Amulet Replicate the US Fertility Playbook in a Sub-Scale European Footprint?

We are launching primary research to determine what TFP's UK and Polish footprint really delivers operationally under BSP's ownership, and whether Amulet's US Fertility playbook can be transplanted into a sub-scale European platform.

On 7 May 2026, Amulet Capital Partners announced the acquisition of TFP Fertility Group from Benefit Street Partners, a credit-focused subsidiary of Franklin Templeton. Financial terms were not disclosed. The asset is a 10-clinic network with 21 satellite or referral centres across the UK and Poland, a perimeter materially narrower than the 19-clinic, six-country group that emerged from the 2021 combination of TFP and VivaNeo. Franky Lee of BSP described the exit using one revealing word: "repositioning." That word, more than any number in the press release, frames the investment debate.

The financial picture is partial by design. TFP delivered roughly GBP 51 million in revenue and over 10,000 IVF cycles annually at the point of Impilo's 2019 acquisition. The 2021 combined entity guided to around EUR 110 million in revenue and 24,000 cycles. Third-party estimates now place a single TFP legal entity at USD 24.5 million in revenue with 249 employees, but that almost certainly understates the consolidated group. What is clear is that between 2021 and 2026, continental European assets in Germany, Austria, the Netherlands and Denmark either left the perimeter or were not part of the transaction. The seller's language suggests the former.

The bull case is straightforward. European IVF is one of the most structurally tailwind-rich subsectors in healthcare services, with market sizing forecasts ranging from a 9% to 15% CAGR through the early 2030s. Amulet has a direct precedent in US Fertility, a platform it built from a 2020 partnership with Shady Grove Fertility into a network supporting more than 120 physicians and over 30,000 IVF cycles annually. The bear case is equally legible. TFP at 10 clinics is sub-scale against IVI-RMA's roughly 70 clinics and the merged GeneraLife and Eugin group. UK self-pay sensitivity, inconsistent NHS reimbursement, and AI-driven embryology disruption all compress the runway for mid-size chains that cannot match the lab investment of scaled peers.

The catalyst window is the first 90 days. Bolt-on M&A, continental re-entry, and capex commitments will be set in this period. Amulet is investing out of its third fund, which closed in July 2024 at approximately USD 1.2 billion after being oversubscribed. The firm has roughly USD 2.5 billion in regulatory AUM. Capital is not the constraint. Execution and perimeter strategy are.

Key Insights

The seller's language is the most revealing single data point in the deal. Franky Lee, BSP Managing Director, framed the exit around "the successful investment and repositioning of TFP." Repositioning is not the vocabulary of organic growth. It is the vocabulary of a credit-led owner working an asset back to PE-saleable condition. BSP is an alternative credit firm with USD 92 billion in AUM focused on direct lending, real estate debt and structured credit. Its ownership of TFP almost certainly emerged from a debt-led position rather than a buyout, which makes the divergence between the 2021 perimeter and the 2026 perimeter the central forensic question of the deal.

The geographic narrowing is the financial story the press release does not tell. In 2021, TFP and VivaNeo combined to operate 19 clinics across six countries with EUR 110 million in revenue and 24,000 cycles. The 2026 asset is 10 clinics across two countries. The German, Austrian, Dutch and Danish clinics that came in via VivaNeo are either divested, carved out, or in a separate vehicle. Whether those assets were sold, written down, or transferred to other holders during the BSP ownership period materially changes the implied multiple Amulet paid and the strategic logic of the platform Amulet has just bought.

Amulet has a direct fertility playbook and is replaying it. In 2020, Amulet partnered with Shady Grove Fertility to form US Fertility as the first investment from Amulet Capital Fund II. USF combined with Ovation Fertility in 2023 and brought in L Catterton as co-lead investor in November 2025, with Amulet retaining significant ownership. The USF platform now supports more than 120 physicians performing over 30,000 IVF cycles annually and has built integrated ancillary services across ASC, lab, pharmacy, genetics, nutrition and cryostorage. The TFP thesis is almost certainly a European translation of that template.

The competitive set is consolidating around far larger platforms. CARE Fertility sits inside Nordic Capital. GeneraLife merged with Eugin in 2023 to form one of Europe's largest groups. IVI-RMA Global, KKR-backed since 2022 at a USD 3.9 billion EV, operates approximately 70 clinics globally. The US Fertility transaction was financed through an USD 825 million first-lien term loan B due 2032 and USD 1.71 billion in new cash and rollover equity. TFP at 10 clinics enters this peer set as a consolidation vehicle, not a category leader. The bolt-on pipeline is the variable that determines whether that gap closes.

Polish reimbursement is the most underappreciated structural tailwind. Poland relaunched its government IVF reimbursement programme in 2024, creating a defined-payer growth lane for TFP's Polish clinics. TFP is currently the third-largest provider in Poland. In the UK, the dynamic runs the other way. NHS funding cycles are inconsistent across regions and the high self-pay mix supports private clinic economics in normal conditions but exposes the business to cost-of-living sensitivity. The mix between these two payer environments will define UK cycle volume and pricing power over the next two years.

Cycle pricing economics define the unit-level risk. European IVF cycles run between EUR 4,000 and EUR 10,000 each, with high cost remaining a barrier to widespread utilisation in markets with limited public funding. TFP's reported quality metrics, including 99% of patients reporting they would recommend the clinics to family or friends, support pricing power. But UK fertility chains typically run 18% to 25% EBITDA margins, and where TFP sits within that band is a function of lab utilisation and clinic-level cycle density. Both are scale-driven.

Participation Opportunity

Woozle Research is inviting professional investors to sponsor or co-sponsor this primary research. Participation is collaborative. All funds receive full access to research outputs including interview summaries, transcripts, and the final synthesis report.

Launch: 18 May 2026
Delivery: 1 June 2026
Participation: Limited to 5 funds
Catalyst: Sponsor-to-sponsor exit from credit owner, perimeter reset, new ownership 90-day strategic window
Research: 25+ TFP and former VivaNeo clinical and operational interviews, 20+ UK and Polish referring physician and patient channel checks, 15+ competitor and industry participant interviews including CARE Fertility, IVI-RMA and GeneraLife/Eugin
Deliverables: raw data, transcripts, synthesis report, analyst access

This research will proceed with a minimum of one fund and is limited to a maximum of five.

The Catalyst

The most interesting deals are the ones where the seller's identity tells you more than the buyer's press release. BSP is a credit firm. It does not run buyout playbooks. Its ownership of TFP almost certainly originated as a credit position, possibly via debt-for-equity conversion following Impilo's 2019 tenure, and what happened between then and now is the part of the story not yet in the public domain. The perimeter shrank. The continental European clinics that came in with VivaNeo are no longer part of the asset. Lee's "repositioning" is the only public confirmation that the intervening years involved active surgery on the business.

The more troubling narrative is that the geographic retrenchment reflects forced disposals rather than strategic focus. Spain, the Czech Republic and Denmark are the dominant fertility tourism corridors in Europe. A UK and Poland footprint cuts TFP out of those flows. CARE Fertility in the UK has Nordic Capital backing and is the immediate competitor for UK self-pay patients. GeneraLife and Eugin together operate across the continental markets TFP has exited. IVI-RMA, with roughly 70 clinics and KKR's capital behind it, is the scaled benchmark. The risk is that TFP's smaller footprint constrains lab utilisation economics, genetics partnership leverage, and the brand pull that drives international patient referrals.

The counter-narrative, and almost certainly Amulet's underwriting case, is that the divestitures cleaned the asset and that Amulet is buying a focused platform at a reset valuation in a market with structural demand tailwinds. Infertility affects approximately one in six couples globally, and the average total fertility rate in the European Union has remained below the population replacement level of 2.1 children per woman for decades. Italy, Spain and Portugal sit around 1.3 to 1.4 births per woman. Demand is not the question. Platform economics and competitive scale are.

The human element matters here. Jude Fleming, TFP's Group CEO, has now steered the business through Impilo, the VivaNeo combination, BSP ownership and now Amulet. Andrew Came preceded her at the time of the 2019 Impilo deal. That continuity through three ownership cycles is unusual and tells you something about the operational discipline of the management team. Jay Rose, Amulet's co-founder, led the 2020 US Fertility formation and has been explicit about the Amulet thesis on reproductive medicine: expanding the range of support services available to physician partner practices. The TFP version of that thesis will look similar, but the European regulatory and reimbursement architecture is fundamentally different from the US.

The next 90 days are the window in which capex commitments, bolt-on pipeline, and continental re-entry decisions will be made. The first concrete signals will be UK independent IVF clinic activity, Polish bolt-ons, and any move into Germany, Spain or the Czech Republic. The HFEA annual data release will confirm TFP's cycle volume and success rates against CARE Fertility and the UK independents. The leveraged loan market may surface the deal's capital structure and implied valuation. All of these are observable. None of them resolve the underlying operational question.

Key Intelligence Questions

The research will focus on the commercial and operational dynamics that determine whether TFP can grow at or above the European market rate, whether Amulet's USF playbook translates, and whether the bolt-on pipeline is real or aspirational. Each question targets a specific input to the investment model.

Perimeter Reality: What Actually Happened Under BSP?

The most consequential unknown in the entire deal is what happened to the continental European VivaNeo assets between 2021 and 2026. The 19-clinic, six-country group described in the 2021 combination announcement is not the 10-clinic, two-country group that changed hands in May 2026. The German, Austrian, Dutch and Danish clinics either were divested during BSP's ownership, are sitting in a separate vehicle, or were structurally excluded from the deal perimeter. Each of these scenarios implies a different valuation framework and a different strategic outlook for Amulet.

Public filings will eventually surface the legal entity changes, but the operational reality, including which clinics closed, which were sold, to whom, and at what implied multiples, is not in the public domain. Former VivaNeo employees and continental European fertility market participants are uniquely positioned to reconstruct the timeline.

We are asking: which of the original VivaNeo continental clinics are still operating, who owns them now, and what does the trajectory of cycle volumes and clinical staffing at TFP's UK and Polish sites look like during the BSP ownership period?

UK Patient Channel: TFP vs. CARE Fertility

The UK fertility market is effectively a duopoly at the platform level, with TFP and CARE Fertility competing for self-pay patients across an inconsistent NHS-funded landscape. Brand preference, success-rate perception, pricing sensitivity and referral conversion are the operational variables that determine TFP's UK cycle volume trajectory. None of these are visible in financial reporting or HFEA data alone.

The cost-of-living environment in the UK adds pressure to self-pay economics. Cycles priced at GBP 5,000 to GBP 8,000 are discretionary spending. Patient acquisition cost, conversion funnels from initial consultation to cycle commitment, and the role of referring NHS GPs in directing patients to specific private providers are the determinants of unit economics.

We are asking: how do UK self-pay patients and referring physicians rank TFP against CARE Fertility and the independents on price, success rates, and patient experience, and what is the conversion trajectory from consultation to paid cycle across the network?

Polish Reimbursement Penetration

Poland's government IVF reimbursement programme, relaunched in 2024, is the most defined-payer growth lane in TFP's portfolio. TFP is the third-largest provider in Poland, behind two scaled domestic competitors. The structural question is how quickly TFP can capture reimbursement-funded volume, what the competitive response from local providers looks like, and whether the programme is durable across Polish political cycles.

Reimbursement-funded cycles carry different unit economics from self-pay cycles. The mix between government-funded and private-pay volume will determine whether the Polish footprint becomes the platform's growth engine or a low-margin volume anchor.

We are asking: what is TFP's current share of reimbursement-funded cycles in Poland, how is the competitive dynamic evolving since the programme relaunched, and what is the political durability of the funding envelope through the next electoral cycle?

Bolt-On Pipeline and Continental Re-Entry

Amulet's track record at US Fertility was built on bolt-on M&A and the addition of ancillary services. The European market is more fragmented at the independent clinic level than the US was when USF was formed. The question is which targets Amulet is underwriting, whether the strategy is UK consolidation, Polish density, continental re-entry, or all three, and how the bolt-on multiples compare to the implied entry multiple on TFP itself.

Continental re-entry would be the most informative signal. A bolt-on in Germany, Spain or the Czech Republic would confirm that the perimeter narrowing was financial rather than strategic, and that Amulet intends to rebuild the cross-border patient referral economics that the standalone UK and Poland platform cannot deliver.

We are asking: which specific bolt-on targets are Amulet and TFP management evaluating across the UK, Poland and continental Europe, what is the indicative pricing environment for independent fertility clinics in those markets, and how does the M&A pipeline reconcile with the underwriting case Amulet would have presented to its LPs?

AI Embryology and Lab Investment

The competitive frontier in fertility services is shifting toward AI-driven embryo evaluation, laboratory automation and telefertility platforms. IVI-RMA and Vitrolife have the scale to invest in proprietary embryology and lab consumables. Mid-size chains face a capex disadvantage. TFP's ability to invest at the lab level, either through proprietary development or through partnerships with scaled equipment providers like Vitrolife, will determine its competitive position over the next three to five years.

This is not purely a technology question. Embryologist talent, lab throughput, and live birth rate per cycle are operational metrics that compound. Falling behind on lab investment shows up in success-rate data with a two- to three-year lag, by which point the brand damage is already priced into patient flow.

We are asking: what is TFP's current lab investment trajectory, how do its live birth rates per cycle compare to CARE Fertility, GeneraLife and IVI-RMA across comparable patient demographics, and what is the technology adoption gap that Amulet's capital will need to close?

How to Participate

Woozle Research is inviting professional investors to sponsor or co-sponsor this primary research. Participation is collaborative. All funds receive full access to research outputs including interview summaries, transcripts, and the final synthesis report.

Launch: 18 May 2026
Delivery: 1 June 2026
Participation: Limited to 5 funds
Catalyst: Sponsor-to-sponsor exit from credit owner, perimeter reset, new ownership 90-day strategic window
Research: 25+ TFP and former VivaNeo clinical and operational interviews, 20+ UK and Polish referring physician and patient channel checks, 15+ competitor and industry participant interviews
Deliverables: raw data, transcripts, synthesis report, analyst access

This research will proceed with a minimum of one fund and is limited to a maximum of five.

This document is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Woozle Research conducts primary research on behalf of institutional investors. All research is conducted in compliance with applicable regulations.